Regenxbio Inc
Regenxbio Inc is a healthcare company that develops gene therapies to treat various diseases.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Regenxbio's stock, with a target price of $36.82, indicating strong potential growth.
Financial Health
Regenxbio is generating strong revenue and cash flow, with good profit margins indicating healthy operations.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring RGNX
Gene Therapy's Regulatory Tailwind
Sarepta Therapeutics' stock surged after the FDA re-approved its gene therapy for muscular dystrophy, signaling a positive turn for the industry. This development creates a potential tailwind for other biotech companies specializing in novel treatments for rare genetic diseases.
Published: July 30, 2025
Explore BasketPioneers In Rare Disease Therapy
The FDA's approval of PTC Therapeutics' drug for the rare disorder PKU marks a significant advancement in metabolic disease treatment. This event creates an investment opportunity by highlighting the growth potential of other biopharmaceutical companies specializing in therapies for rare genetic conditions.
Published: July 29, 2025
Explore BasketGene Therapy's Competitive Shift
The European Medicines Agency's recent rejection of Sarepta Therapeutics' gene therapy creates a potential opening for its competitors. This theme focuses on the biopharmaceutical companies that stand to benefit from this regulatory hurdle in the Duchenne muscular dystrophy market.
Published: July 25, 2025
Explore BasketWhy You’ll Want to Watch This Stock
NAV AAV Platform
A proprietary AAV platform underpins many programmes and collaborations — it may enable broad applications, though development is costly and outcomes uncertain.
Clinical Milestones
Trial readouts and regulatory steps tend to drive share movements; positive data can increase value, while setbacks are common and may be swift.
Partnerships Matter
Collaborations can provide funding and expertise and help de‑risk programmes, but commercial returns depend on successful development and approvals.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals develops treatments for diseases including cystic fibrosis and cancer.
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals is a leading biotechnology company that develops and manufactures innovative medicines for serious medical conditions.
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing therapeutics based on RNA interference (RNAi).
